Renaissance Technologies's PRME Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 1.15 M shares of Prime Medicine, Inc. (PRME) worth $3.99 M, representing 0.01% of the portfolio. First purchased in 2023-Q4, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in PRME, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 911,270 shares. Largest reduction occurred in Q2 2024, reducing 362,400 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Prime Medicine (PRME) Holding Value Over Time
Track share changes against reported price movement
Quarterly Prime Medicine (PRME) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2023 | +53,292 | New Buy | 53,292 | $8.86 |
| Q1 2024 | +309,108 | Add 580.03% | 362,400 | $7.00 |
| Q2 2024 | -362,400 | Sold Out | 0 | $0.00 |
| Q3 2024 | +20,000 | New Buy | 20,000 | $3.87 |
| Q4 2024 | -20,000 | Sold Out | 0 | $0.00 |
| Q1 2025 | +447,600 | New Buy | 447,600 | $1.99 |
| Q2 2025 | -224,200 | Reduce 50.09% | 223,400 | $2.47 |
| Q3 2025 | +911,270 | Add 407.91% | 1.13 M | $5.54 |
| Q4 2025 | +14,489 | Add 1.28% | 1.15 M | $3.47 |
Renaissance Technologies's Prime Medicine Investment FAQs
Renaissance Technologies first purchased Prime Medicine, Inc. (PRME) in Q4 2023, acquiring 53,292 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Prime Medicine, Inc. (PRME) for 9 quarters since Q4 2023.
Renaissance Technologies's largest addition to Prime Medicine, Inc. (PRME) was in Q3 2025, adding 1,134,670 shares worth $6.29 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 1,149,159 shares of Prime Medicine, Inc. (PRME), valued at approximately $3.99 M.
As of the Q4 2025 filing, Prime Medicine, Inc. (PRME) represents approximately 0.01% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Prime Medicine, Inc. (PRME) was 1,149,159 shares, as reported at the end of Q4 2025.